$BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC)$ , once known for "burning cash," has now turned things around with the outstanding performance of Brukinsa, turning profitable and surpassing Hansoh Pharmaceutical in market value, becoming the new "king of pharma" in the A-share market!
This is not just about the rise in stock prices, but a massive breakthrough in BeiGene's R&D and innovation. The future growth prospects of its core products are extremely promising, especially with the ongoing expansion into global markets and the continuous enrichment of its R&D pipeline. BeiGene is poised for sustained growth, and its business outlook is clear.
This presents an investment opportunity that shouldn’t be overlooked.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
